Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms
- 17 May 2017
- journal article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 131 (11) , 1107-1121
Abstract
Chronic inflammation that progressively disrupts the lung tissue is a hallmark of cystic fibrosis (CF). In mice, vardenafil, an inhibitor of phosphodiesterase type 5 (PDE5), restores transepithelial ion transport and corrects mislocalization of the most common CF mutation, F508del-CFTR. It also reduces lung pro-inflammatory responses in mice and in patients with CF. To test the hypothesis that macrophages are target effector cells of the immunomo-dulatory effect of vardenafil, we isolated lung macrophages from mice homozygous for the F508del mutation or invalidated for the cftr gene and from their corresponding wild-type (WT) littermates. We then evaluated the effect of vardenafil on the classical M1 polarization, mirroring release of pro-inflammatory cytokines. We confirmed that macrophages from different body compartments express CF transmembrane conductance regulator (CFTR) and showed that vardenafil targets the cells through PDE5- and CFTR-dependent mechanisms. In the presence of the F508del mutation, vardenafil down-regulated overresponses of the M1 markers, tumour necrosis factor (TNF)-α and inducible nitric oxide synthase (NOS)-2. Our study identifies lung macrophages as target cells of the anti-inflammatory effect of vardenafil in CF and supports the view that the drug is potentially beneficial for treating CF as it combines rescue of CFTR protein and anti-inflammatory properties.Keywords
This publication has 46 references indexed in Scilit:
- Dysregulated Proinflammatory and Fibrogenic Phenotype of Fibroblasts in Cystic FibrosisPLOS ONE, 2013
- Protective and pathogenic functions of macrophage subsetsNature Reviews Immunology, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences, 2011
- The cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in maturation stage ameloblasts, odontoblasts and bone cellsBone, 2010
- Disease-causing Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Determine the Functional Responses of Alveolar MacrophagesJournal of Biological Chemistry, 2009
- Azithromycin Reduces Exaggerated Cytokine Production by M1 Alveolar Macrophages in Cystic FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- Revisiting the Role of Cystic Fibrosis Transmembrane Conductance Regulator and Counterion Permeability in the pH Regulation of Endocytic OrganellesMolecular Biology of the Cell, 2009
- Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Macrophages Directly Contribute to the Exaggerated Inflammatory Response in Cystic Fibrosis Transmembrane Conductance Regulator−/− MiceAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- CFTR Expression in Human Neutrophils and the Phagolysosomal Chlorination Defect in Cystic FibrosisBiochemistry, 2006